Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch

Executive Summary

Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.

You may also be interested in...

ThromboGenics’ Jetrea Clears Advisory Panel, But Questions On Population Size Remain

FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 10-0 that the risk-benefit ratio of ocriplasmin for vitreomacular adhesions is positive, and 6-3 that no additional pre-approval studies are needed.

ThromboGenics Ocriplasmin’s Advisory Panel Likely To Focus On Safety

ThromboGenics will seek to convince the Dermatologic and Ophthalmic Drugs Advisory Committee that further safety studies should not be made a condition of approval of its ocriplasmin for symptomatic vitreomacular adhesion, including macular hole.

Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts